Geneva Partners’s iShares Biotechnology ETF IBB Stock Holding History

Geneva Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,958	Closed	-$2.25M	–	97
2021 Q1	$2.25M	Sell	14,958 -2,096	-12%	-$333K	1.16%	30
2020 Q4	$2.58M	Sell	17,054 -2,861	-14%	-$409K	1.36%	25
2020 Q3	$2.7M	Sell	19,915 -4,474	-18%	-$607K	1.65%	26
2020 Q2	$3.33M	Buy	+24,389	New	+$3.11M	2.34%	16

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Geneva Partners's IBB Position: Q2 2021 in Review

Geneva Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 14,958 shares — an estimated $2.25M sold.

Geneva Partners first reported a position in IBB in Q2 2020 and held it in 4 quarters. The position peaked at $3.33M in Q2 2020. 863 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

Geneva Partners reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
Geneva Partners sold 14,958 iShares Biotechnology ETF shares in Q2 2021, an estimated $2.25M.
Geneva Partners first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 4 quarters.
Geneva Partners's iShares Biotechnology ETF position peaked at $3.33M in Q2 2020.
863 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on Geneva Partners's 13F filing for Q2 2021, filed 6 Aug 2021.